Breaking News Instant updates and real-time market news.

VIAB

Use VIAC, VIACA

$25.27

(0.00%)

, IYR

DJ US Real Estate Index Fund

$85.88

(0.00%)

09:40
03/25/19
03/25
09:40
03/25/19
09:40

Unusually active option classes on open March 25th

Unusual total active option classes on open include: Viacom (VIAB), iShares DJ US Real Estate Index Fund (IYR), Nokia (NOK), Health Care Sector SPDR ETF (XLV), ProShares UltraPro Short QQQ (SQQQ), Cronos Group (CRON), Utilities Sector SPDR ETF (XLU), Apple (AAPL), JPMorgan (JPM), and EWZ (EWZ).

VIAB

Use VIAC, VIACA

$25.27

(0.00%)

IYR

DJ US Real Estate Index Fund

$85.88

(0.00%)

NOK

Nokia

$5.94

(0.00%)

XLV

Health Care Select Sector SPDR

$90.70

(0.00%)

SQQQ

ProShares UltraPro Short QQQ

$10.36

(0.00%)

CRON

Cronos Group

$19.45

(0.00%)

XLU

Utilities SPDR

$58.60

(0.00%)

AAPL

Apple

$191.11

(0.00%)

JPM

JPMorgan

$99.78

(0.00%)

EWZ

MSCI Brazil Index

$40.34

(0.00%)

  • 25

    Mar

  • 26

    Mar

  • 12

    Apr

  • 20

    May

VIAB Use VIAC, VIACA
$25.27

(0.00%)

02/06/19
BRRR
02/06/19
NO CHANGE
Target $35
BRRR
Outperform
Barrington expects Pluto TV to accelerate momentum in key Viacom demographics
Barrington analyst James Goss kept his Outperform rating and $35 price target on Viacom with a positive view of its Pluto TV platform as a component of its direct-to-consumer strategy. The analyst sees the services as an "important link for Viacom in accessing its young target demo" in a form factor "attractive to the user base". While not expected to make a meaningful impact on Q2, Goss adds that Pluto TV offers the "ability to distribute and monetize the cable network group's significant IP portfolio".
02/05/19
IMPC
02/05/19
NO CHANGE
IMPC
Imperial Capital raises FY19 estimates on Viacom after Q1 beat
Imperial Capital analyst Megan Barnett maintained an Outperform rating and $37 price target on Viacom shares, after Viacom beat the firm's and consensus estimates when it reported Q1 results. Barnett raised her FY19 EPS estimate for Viacom to $1.12 from $1.02 due to the company's Q1results.
01/24/19
SOCG
01/24/19
DOWNGRADE
SOCG
Hold
Viacom downgraded to Hold from Buy at Societe Generale
03/13/19
03/13/19
DOWNGRADE
Target $66

Neutral
Roku downgraded to Neutral after 160% rally off lows at Macquarie
As previously reported, Macquarie analyst Tim Nollen downgraded Roku to Neutral from Outperform following a 162% rise in the stock from its lows since Christmas. He sees the stock's current valuation as full given the rising competition in the ad-supported video on-demand, or AVOD, area from services such as Viacom's (VIAB) Pluto TV, Amazon's (AMZN) ad-supported channels and a potential service expected to be announced by Apple (AAPL) on March 25. Nollen raised his price target on Roku shares to $66 from $57.
IYR DJ US Real Estate Index Fund
$85.88

(0.00%)

NOK Nokia
$5.94

(0.00%)

02/01/19
ADAM
02/01/19
NO CHANGE
Target $8
ADAM
Buy
Nokia results show targets and thesis intact, says Canaccord
Canaccord analyst T. Michael Walkley noted Nokia reported Q4 results consistent with his estimates. He believes the company is positioned as a long-term industry leader as 5G begins to ramp. The analyst said his Buy thesis and the company's 2020 targets remain intact. Walkley reiterated his Buy rating and raised his price target to $7.50 from $7.00 on Nokia shares.
01/23/19
MKMP
01/23/19
NO CHANGE
Target $7.5
MKMP
Buy
Nokia Q4 earnings should be solid, says MKM Partners
MKM Partners analyst Michael Genovese kept his Buy rating and $7.50 price target on Nokia (NOK) ahead of its Q4 results, saying that earnings should be solid with evidence of 5G contribution, even though the outlook on its potential "won't settle the debate". The analyst notes that T-Mobile's (TMUS) 5G network build demand should also yield a good Q1 outlook with added contribution coming from the accelerated 5G plans from KT (KT) and SK Telecom in South Korea. Genovese adds that the 5G debate centers around investment plans by AT&T (T) and Verizon (VZ), but his checks indicate that the former has not made any final decisions on the timing.
01/08/19
RAJA
01/08/19
UPGRADE
Target $7.5
RAJA
Outperform
Nokia upgraded to Outperform at Raymond James
As previously reported, Raymond James upgraded Nokia to Outperform from Market Perform with a $7.50 price target. Analyst Simon Leopold sees improving trends led by wireless spending that will aid Nokia's other segments of routing, optical and mobility. Simon also expects Nokia to benefit from the global backlash against Huawei, and views the company as advantaged given the diversity of its portfolio.
03/20/19
NORD
03/20/19
DOWNGRADE
NORD
Hold
Nokia downgraded to Hold from Buy at Nordea
XLV Health Care Select Sector SPDR
$90.70

(0.00%)

SQQQ ProShares UltraPro Short QQQ
$10.36

(0.00%)

CRON Cronos Group
$19.45

(0.00%)

03/11/19
03/11/19
DOWNGRADE

Underperform
Cronos Group downgraded to Underperform, valuation 'elevated,' says BMO Capital
As previously reported, BMO Capital downgraded Cronos Group to Underperform from Market Perform. Analyst Tamy Chen believes Cronos' production ramp is behind other licensed producers and views valuation as "elevated."
03/11/19
BMOC
03/11/19
DOWNGRADE
BMOC
Underperform
Cronos Group downgraded to Underperform from Market Perform at BMO Capital
03/05/19
COWN
03/05/19
INITIATION
COWN
Market Perform
Cronos Group initiated with a Market Perform at Cowen
Cowen analyst Vivien Azer started Cronos Group (CRON) with a Market Perform rating and C$29 price target. The analyst likes the company's story as an asset-light, global low-cost producer with operational support and invested capital from Altria Group (MO). However, Azer says the stock's current valuation prevents her from taking a more constructive position at this time.
03/14/19
COWN
03/14/19
NO CHANGE
COWN
Narrow U.S. cannabis bills have better prospects than broad ones, says Cowen
Cowen analyst Jaret Seiberg said it is hard for him to see a scenario in the 116th Congress in which Senate Majority Leader Mitch McConnell holds a vote on legislation to fully legalize cannabis, as too many senators see no political upside for McConnell to schedule such a vote. Given this view, Seiberg believes that prospects are better for narrower bills that could get attached to spending packages and other measures than for broader bills that would legalize recreational use. Of the narrower bills introduced in the U.S. so far, Seiberg believes the SAFE Act on cannabis banking has the best shot before the 2020 election. Publicly traded companies in the cannabis space include Aphria (APHA), Aurora Cannabis (ACB), CV Sciences (CVSI), CannTrust Holdings (CNTTF), Canopy Growth (CGC), Cronos Group (CRON), General Cannabis (CANN), India Globalization Capital (IGC), MediPharm Labs (MLCPF) and Tilray (TLRY).
XLU Utilities SPDR
$58.60

(0.00%)

04/02/18
MSCO
04/02/18
NO CHANGE
MSCO
Utilities view lowered to Equal Weight at Morgan Stanley
Morgan Stanley equity strategist Michael Wilson said he thinks many of the risks facing the market have now been priced in and he sees value in the S&P, which is currently at the low end of his target near-term range ahead of what will likely be a strong Q1 earnings season. However, he is moving the Utilities sector to Equal Weight from Overweight, stating that this is not a sell call for those who recently bought the stocks but that a tactical overweight after recent relative outperformance no longer makes sense.
AAPL Apple
$191.11

(0.00%)

03/22/19
JPMS
03/22/19
UPGRADE
Target $65
JPMS
Overweight
JPMorgan upgrades Lumentum to Overweight on iPhone volume stabilization
JPMorgan analyst Samik Chatterjee upgraded Lumentum Holdings (LITE) to Overweight from Neutral and raised his price target for the shares to $65 from $50. The stock closed yesterday up $2.44, of 5%, to $52.10. The analyst sees a "solid" outlook for the company's telecom business amid "strong" growth led by 5G investments and upside to synergy targets relative to recent acquisition of Oclaro. Further, he sees limited downside risk relative to volume expectations for Apple's (AAPL) iPhone, which he notes has been a "key driver of sentiment on the shares." Stabilization of its iPhone volume outlook should drive focus back to the "strong" fundamentals in Lumentum's primary telecom business, Chatterjee tells investors in a research note.
03/22/19
MSCO
03/22/19
NO CHANGE
MSCO
Overweight
Apple streaming service timing, robustness key details, says Morgan Stanley
Morgan Stanley analyst Katy Huberty said she expects next Monday's special event from Apple to be focused on new Services launches, specifically a streaming video on demand service and likely a paid subscription news and magazine service. Huberty believes that besides the launch of an Apple Media bundle, which she would view as the most bullish potential announcement, the inclusion of video content from other programmers would be a positive and the launch timing and robustness of the offerings are the most important details to watch. A meaningful delay in the launch of original video content could hamper customer adoption and pricing at or above market for a stand-alone streaming video service could also slow adoption, said Huberty, who has an Overweight rating on Apple shares.
03/25/19
BTIG
03/25/19
NO CHANGE
Target $220
BTIG
Buy
Apple price target raised to $220 from $189 at BTIG
BTIG analyst Walter Piecyk raised his price target on Apple to $220 and kept his Buy rating ahead of its product event today, saying that while the rally of the stock price could stall, his new target assumes the company will return to growth in 2020. The analyst notes that while the recent data points have not been positive for Apple's iPhone business expectations, he continues to expect abating lengthening of the product cycle to materialize in 2020. Piecyk adds that stock buybacks and the company's capital program should be the primary driver Apple's earnings growth.
03/21/19
RHCO
03/21/19
NO CHANGE
RHCO
Apple event may be negative for Netflix, positive for Lions Gate, says SunTrust
SunTrust analyst Matthew Thornton previews Apple's (AAPL) media event scheduled for March 25th, saying the company is likely to unveil a Video Service. The analyst believes that an Apple OTT service could be a positive for Lions Gate (LGF.B) given the participation of the Starz networks but negative for Netflix (NFLX) "if Apple can offer compelling content bundles at compelling prices with a compelling UI and ubiquitous access". Thornton adds that Apple's bundling of its Music with video subscriptions and news subscriptions may be a negative for Spotify (SPOT) and a "modest incremental negative" for Roku (ROKU) if Apple's service app is not on its service.
JPM JPMorgan
$99.78

(0.00%)

03/19/19
KEYB
03/19/19
DOWNGRADE
KEYB
Sector Weight
Worldpay downgraded to Sector Weight after Fiserv deal at KeyBanc
As previously reported, KeyBanc analyst Josh Beck downgraded Worldpay (WP) to Sector Weight from Overweight after the company and FIS (FIS) announced a deal, quickly adding another mega-deal in the wake of Fiserv (FISV)-First Data (FDC) and Global Payments (GPN)-Heartland Payment Systems. The analyst thinks this transaction is likely to expand the M&A discussion around Global Payments, TSYS (TSS), EVO Payments (EVOP), and i3 Verticals (IIIV) and sees paths to accretion should management teams further endorse a scale strategy. Future processing competition could increase among Global Payments, TSYS, First Data, and JPMorgan (JPM), but it remains too early to gauge, he contends.
03/25/19
JEFF
03/25/19
NO CHANGE
JEFF
Jefferies downgrades Financials to Underweight on 'shocking' Fed meeting
Jefferies analyst Steven DeSanctis is "very surprised" by last week's Federal Reserve's decision taking rate hikes completely off table in 2019. The "shocking" Fed meeting means lower rates for longer, which is not good for Financials, DeSanctis tells investors in a research note. A "lack of catalysts and weaker earnings growth" going forward for the entire sector, not just banks, means an Underweight rating on the space makes sense, says the analyst. As such, he downgraded his rating on the Financial sector to Underweight from Market Weight. Publicly traded companies in the space include Bank of America (BAC), Citi (C), Goldman Sachs (GS), JPMorgan (JPM), Morgan Stanley (MS), U.S. Bancorp (USB) and Wells Fargo (WFC).
03/06/19
03/06/19
NO CHANGE

JPMorgan files $130.14M mixed securities shelf
02/28/19
BMOC
02/28/19
NO CHANGE
Target $116
BMOC
Market Perform
JPMorgan price target lowered to $116 from $123 at BMO Capital
BMO Capital analyst James Fotheringham lowered his price target on JPMorgan to $116 and kept his Market Perform rating, citing the company's Investor Day presentation that lowered expectations for net interest income as well as performance of its corporate & investment bank and wealth management segments. The analyst believes that other large-cap banks, fin-tech companies, and specialty lenders offer greater opportunity, even though his price target still implies a 13% return for JPMorgan stock.
EWZ MSCI Brazil Index
$40.34

(0.00%)

TODAY'S FREE FLY STORIES

CLDR

Cloudera

$10.02

0.16 (1.62%)

09:00
12/06/19
12/06
09:00
12/06/19
09:00
Recommendations
Cloudera analyst commentary  »

Cloudera price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

ORGS

Orgenesis

$2.58

-0.19 (-6.86%)

09:00
12/06/19
12/06
09:00
12/06/19
09:00
Hot Stocks
Orgenesis, Theracell to launch cell therapy platform in HYGEIA Group's network »

Orgenesis announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:00
12/06/19
12/06
09:00
12/06/19
09:00
General news
Treasury Action: yields have jumped on the blowout jobs report »

Treasury Action: yields…

ALXN

Alexion

$107.42

-8.07 (-6.99%)

09:00
12/06/19
12/06
09:00
12/06/19
09:00
Hot Stocks
Breaking Hot Stocks news story on Alexion 

Alexion trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 16

    Dec

HAPP

Happiness Biotech

$4.91

(0.00%)

08:59
12/06/19
12/06
08:59
12/06/19
08:59
Initiation
Happiness Biotech initiated  »

Happiness Biotech…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARAY

Accuray

$2.86

0.09 (3.26%)

08:59
12/06/19
12/06
08:59
12/06/19
08:59
Conference/Events
Accuray management to meet with Lake Street »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

EW

Edwards Lifesciences

$242.87

-3.41 (-1.38%)

08:58
12/06/19
12/06
08:58
12/06/19
08:58
Recommendations
Edwards Lifesciences analyst commentary  »

Edwards Lifesciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COO

Cooper Companies

$313.10

1 (0.32%)

08:57
12/06/19
12/06
08:57
12/06/19
08:57
Recommendations
Cooper Companies analyst commentary  »

Cooper Companies weakness…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 13

    Dec

ALNA

Allena Pharmaceuticals

$1.95

-0.36 (-15.58%)

08:56
12/06/19
12/06
08:56
12/06/19
08:56
Recommendations
Allena Pharmaceuticals analyst commentary  »

Allena Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

DHR

Danaher

$147.07

-0.25 (-0.17%)

, NIO

NIO Inc.

$2.27

-0.15 (-6.20%)

08:55
12/06/19
12/06
08:55
12/06/19
08:55
Options
Notable open interest changes for December 6th »

Thursday's total…

DHR

Danaher

$147.07

-0.25 (-0.17%)

NIO

NIO Inc.

$2.27

-0.15 (-6.20%)

BABA

Alibaba

$200.04

6.345 (3.28%)

BAC

Bank of America

$33.10

0.3 (0.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 15

    Jan

  • 26

    Feb

CLH

Clean Harbors

$83.13

0.44 (0.53%)

08:53
12/06/19
12/06
08:53
12/06/19
08:53
Recommendations
Clean Harbors analyst commentary  »

Clean Harbors elevated to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

  • 17

    Dec

PD

PagerDuty

$24.99

-0.66 (-2.57%)

08:52
12/06/19
12/06
08:52
12/06/19
08:52
Recommendations
PagerDuty analyst commentary  »

PagerDuty price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCKT

Rocket Pharmaceuticals

$19.76

0.54 (2.81%)

08:49
12/06/19
12/06
08:49
12/06/19
08:49
Recommendations
Rocket Pharmaceuticals analyst commentary  »

Rocket Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

XENE

Xenon Pharmaceuticals

$13.89

-0.31 (-2.18%)

08:49
12/06/19
12/06
08:49
12/06/19
08:49
Hot Stocks
Xenon provides updates on proprietary neurology pipeline programs »

Xenon Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:49
12/06/19
12/06
08:49
12/06/19
08:49
Conference/Events
The Business Roundtable to hold a conference call »

The Business Roundtable…

DE

Deere

$164.60

-0.61 (-0.37%)

08:49
12/06/19
12/06
08:49
12/06/19
08:49
Recommendations
Deere analyst commentary  »

North American ag markets…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YEXT

Yext

$16.62

0.065 (0.39%)

08:47
12/06/19
12/06
08:47
12/06/19
08:47
Recommendations
Yext analyst commentary  »

Yext price target lowered…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TARO

Taro Pharmaceutical

$93.79

-1.14 (-1.20%)

08:46
12/06/19
12/06
08:46
12/06/19
08:46
Hot Stocks
Taro Pharmaceutical CFO Mariano Balaguer to resign »

Taro Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZM

Zoom Video

$69.73

-0.22 (-0.31%)

08:46
12/06/19
12/06
08:46
12/06/19
08:46
Recommendations
Zoom Video analyst commentary  »

Zoom Video price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

08:45
12/06/19
12/06
08:45
12/06/19
08:45
General news
U.S. nonfarm payrolls surged 266k in November »

U.S. nonfarm payrolls…

HEXO

Hexo

$2.06

-0.075 (-3.52%)

, XNET

Xunlei

$4.93

0.02 (0.41%)

08:45
12/06/19
12/06
08:45
12/06/19
08:45
Options
Largest borrow rate increases among liquid names »

Latest data shows the…

HEXO

Hexo

$2.06

-0.075 (-3.52%)

XNET

Xunlei

$4.93

0.02 (0.41%)

CGC

Canopy Growth

$18.58

0.19 (1.03%)

UPRO

Uproar Inc

$63.22

0.35 (0.56%)

SRNE

Sorrento Therapeutics

$3.25

-0.41 (-11.20%)

VSTM

Verastem

$1.26

-0.115 (-8.39%)

ET

Energy Transfer LP

$11.60

0.29 (2.56%)

TTM

Tata Motors

$11.56

-0.28 (-2.36%)

NIO

NIO Inc.

$2.27

-0.15 (-6.20%)

VAL

Valaris

$4.55

0.12 (2.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 16

    Dec

08:45
12/06/19
12/06
08:45
12/06/19
08:45
General news
FX Action: The dollar »

FX Action: The dollar…

CPST

Capstone Turbine

$3.77

-0.11 (-2.84%)

08:44
12/06/19
12/06
08:44
12/06/19
08:44
Hot Stocks
Capstone Turbine appoints Eric Hencken as CFO »

Capstone Turbine…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GEMP

Gemphire Therapeutics

$0.33

-0.0068 (-1.99%)

08:44
12/06/19
12/06
08:44
12/06/19
08:44
Hot Stocks
Gemphire announces stockholder approvals required for NeuroBo merger »

Gemphire Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FNMA

Fannie Mae

$0.00

(0.00%)

, FMCC

Freddie Mac

$0.00

(0.00%)

08:43
12/06/19
12/06
08:43
12/06/19
08:43
Recommendations
Fannie Mae, Freddie Mac analyst commentary  »

Fannie Mae price target…

FNMA

Fannie Mae

$0.00

(0.00%)

FMCC

Freddie Mac

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.